Drugs / DT-168
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07024693 | Jul 2025 → Sep 2026 overdue | Fuchs atrophia gyrata chorioideae et retinae, Fuchs' endothelial dystrophy | Design Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-07 | Design Therapeutics, Inc. | Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results designtx.com ↗ |
| 2025-05-01 | Design Therapeutics, Inc. | Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy designtx.com ↗ |
| 2024-03-19 | Design Therapeutics, Inc. | Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results designtx.com ↗ |
| 2023-04-24 | Design Therapeutics, Inc. | Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 designtx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024693 ↗ |